Table 1

Baseline characteristics of the primary Sjögren's syndrome study population (n=28)

VariableMean±SD or n (%)Median (range)
Age (years)43±1440 (18–70)
Female gender, n (%)27 (96)
Disease duration (months)80±4864 (14–183)
IgG (g/l)22.5±7.421.3 (12.8–41.5)
IgM-Rf (kIU/l)143±16490 (7–783)
Anti-Ro/SSA positive, n (%)28 (100)
Anti-La/SSB positive, n (%)20 (71)
SWS (ml/min)0.42±0.370.31 (0.02–1.47)
Rituximab course number, n (%)
 1st8 (29)
 2nd15 (54)
 3rd3 (11)
 4th2 (7)
ESSPRI6.3±2.26.7 (0.3–9.0)
ESSDAI8±58 (2–18)
 Constitutional domain, n (%)*12 (43)
 Lymphadenopathy domain, n (%)*0 (0)
 Glandular domain, n (%)*17 (61)
 Articular domain, n (%)*8 (29)
 Cutaneous domain, n (%)*4 (14)
 Pulmonary domain, n (%)*3 (11)
 Renal domain, n (%)*1 (4)
 Muscular domain, n (%)*0 (0)
 PNS domain, n (%)*2 (7)
 CNS domain, n (%)*0 (0)
 Haematological domain, n (%)*11 (39)
 Biological domain, n (%)*24 (86)
Patient's GDA58±2260 (15–93)
Physician's GDA53±1655 (20–80)
  • Values are presented as mean±SD unless otherwise indicated.

  • * Number (%) of patients having any degree of activity per ESSDAI domain (score of at least 1).

  • CNS, central nervous system; ESSDAI, EULAR Sjögren's Syndrome Disease Activity Index; ESSPRI, EULAR Sjögren's Syndrome Patients Reported Index; GDA, global disease activity; IgM-Rf, rheumatoid factor; PNS, peripheral nervous system; SWS, stimulated whole salivary flow.